NTX 600
Alternative Names: NTX-600Latest Information Update: 22 Jan 2026
At a glance
- Originator NexEos Bio
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 04 Aug 2025 Preclinical trials in Inflammation in USA (unspecified route) (NexEos Bio pipeline, July 2025)